AUP 65
Alternative Names: AUP-65Latest Information Update: 14 May 2023
Price :
$50 *
At a glance
- Originator Aurealis Therapeutics
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Interferon alpha stimulants; Interleukin 12 stimulants; Interleukin 18 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Apr 2023 Preclinical trials in Cancer in Finland (Intratumoural)(Aurealis Therapeutics pipeline, April 2023)
- 07 Apr 2023 Pharmacodynamics data from a preclinical studies in Cancer released by Aurealis Therapeutic (Aurealis Therapeutics pipeline, April 2023)